Loading...

VYNE VYNE THERAPEUTICS INC Expansion Plans 8-K Filing

VYN

VYN

VYNE THERAPEUTICS INC

(VYNE)

2025 8-K

Investor Presentation

Nasdaq Compliance Extended

Merger Agreement Update

Merger Announcement

Annual Meeting Results

Financial Results

Delisting Notice

Management Changes

Product Expansion

Financial Statements

Financial Results

Corporate Update

Positive Trial Results

Equity Plan Amendment

Financial Results

Positive Drug Data

Financial Results

Financial Results Announcement

Financial Results Announcement

Appointment of Dr. Christin...

Equity Compensation Matters

Financial Results Announcement

Private Placement and Other...

Financial Results Announcement

Financial Results Announcement

License Agreement with Tay ...

Financial Results Announcement

Extension of Option Agreement

Reverse Stock Split

Redemption of Series A Pref...

Special Meeting and Deferre...

External Links:

On July 30, 2025, VYNE Therapeutics Inc. announced the topline results from its Phase 2b trial of Repibresib Gel for treating nonsegmental vitiligo, along with preliminary cash estimates of approximately $39.6 million as of June 30, 2025.

AI Assistant

VYNE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.